GET DAILY SIGNALSJNJ vs UNH: Diverging Healthcare Earnings and What They Mean for Investors
Key Takeaways
- Both healthcare giants reported third-quarter 2026 results in recent weeks, but investor reactions diverged, reflecting different growth and risk profiles.
- JNJ delivered stronger pharmaceutical momentum but was pressured by slowing MedTech growth and a large talc litigation charge.
- UNH posted sharply higher earnings and improving margins, though a post-earnings fade shows investors still question its longer-term growth path.
- Based on trend consistency, margin recovery, and earnings momentum, Tickeron's AI currently favors UNH over JNJ.
- For deeper coverage, explore JNJ Major News and JNJ Today's Price Move, as well as UNH Major News and UNH Today's Price Move.
- To see which automated strategies are best suited to current market conditions, explore Trending AI Robots.
Why These Two Healthcare Names Stand Out
Johnson & Johnson and UnitedHealth Group are two of the most closely watched names in U.S. healthcare, yet they operate at opposite ends of the industry's value chain. JNJ is a diversified pharmaceutical and medical-device maker, while UNH is the nation's largest health insurer and a leading provider of pharmacy and care-delivery services through Optum. Both reported quarterly results in recent weeks, giving investors a fresh read on their respective growth trajectories. This stock comparison is relevant to long-term investors evaluating stability and dividends, as well as traders assessing relative performance and market positioning across two healthcare heavyweights with distinct risk profiles. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Johnson & Johnson’s Q3 Results in Focus
Johnson & Johnson operates two main segments: Innovative Medicine and MedTech. In recent weeks, JNJ reported quarterly revenue of roughly $25.4 billion, up about 5.9% year over year, with adjusted earnings per share of $2.59. Pharmaceutical sales grew 7.7%, led by strong demand for Tremfya and Darzalex, which helped offset erosion from Stelara as it faces biosimilar competition.
However, sentiment was tempered by slower MedTech growth of about 2.5%, driven by softer international demand, pricing pressure in China, and weakness in the Abiomed Impella franchise. A pre-tax charge of roughly $5.5 billion tied to the company's talc settlement offer also weighed on reported earnings. The company raised its full-year sales outlook to about $101.2 billion, but shares still declined in the days following the report. Longer term, JNJ has announced plans to spin off its DePuy Synthes orthopedics unit, a move aimed at sharpening focus and improving MedTech performance.
UnitedHealth Group’s Earnings Momentum
UnitedHealth Group operates through two core divisions: UnitedHealthcare and Optum. In its most recent quarter, UNH reported revenue of about $112.7 billion, roughly flat year over year, while adjusted EPS rose 61% to $4.69. The company's medical care ratio improved meaningfully, a sign that cost-control efforts are taking hold.
Management raised its full-year adjusted EPS guidance to at least $20.50, implying roughly 25% growth. Much of the recent improvement reflects deliberate discipline: UNH has reduced membership in lower-margin Medicare Advantage and Medicaid markets to protect profitability. Even so, shares gave back initial post-earnings gains, as investors weighed a shrinking revenue base against the margin recovery. Over the past year, the stock has recovered substantially from its 2025 lows, supported by leadership changes, a refocus on U.S. healthcare, and restored investor confidence. From what I see, the earnings trajectory here stands out.
Head-to-Head: Business Models and Risks
The two companies differ sharply in business model. JNJ is a product-driven manufacturer of drugs and devices, with revenue tied to innovation cycles, patent expirations, and procedure volumes. UNH is a service-driven payer and care coordinator, with results tied to premiums, medical-cost management, and membership economics.
On growth, JNJ benefits from a strong pharmaceutical pipeline but faces a clear near-term overhang in MedTech and lingering talc litigation. UNH is growing profits rapidly through margin recovery, though its revenue is effectively flat as it intentionally sheds less profitable members. Momentum has favored UNH, which delivered four consecutive quarterly earnings beats, whereas JNJ saw its post-earnings reaction turn negative despite raised guidance.
Risk profiles also diverge. JNJ carries regulatory, patent-cliff, and litigation risks. UNH faces policy and regulatory scrutiny around Medicare Advantage reimbursement and billing practices, which can produce sharp sentiment shifts. On income, both pay dividends, but JNJ has a longer record of consecutive increases, while UNH has grown its payout at a faster double-digit clip in recent years.
Where Tickeron’s AI Points
On a relative basis, Tickeron's AI currently leans toward UNH as the favored name in this pairing. The verdict reflects observable factors rather than a definitive prediction: UNH has demonstrated more consistent earnings momentum, a clear margin-recovery catalyst, and improving cost discipline. In contrast, JNJ shows a more mixed picture, with pharmaceutical strength partly offset by MedTech deceleration and litigation-related charges. Because these signals can shift with new earnings, policy, or clinical data, the AI's preference is best understood as a probabilistic assessment of current relative positioning, not a fixed recommendation. I’m watching this closely as new data emerges.
Exploring AI-Driven Trading Strategies
In my research on names like these, I often turn to Tickeron’s Trending AI Robots to see which automated strategies are performing well in the current environment. The page highlights a curated selection of bots from a much larger universe, focusing on those best aligned with prevailing market conditions. These range from short-term momentum models to longer-horizon trend-following systems, offering a data-driven perspective on approaches that may suit healthcare holdings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for UNH turns negative, indicating new downward trend
UNH saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 55 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 17 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 31 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 39%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 182 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 114 of 245 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.687) is normal, around the industry mean (3.359). P/E Ratio (25.926) is within average values for comparable stocks, (126.681). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.023) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement